🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/01/2022 30,36 32,02 29,43 31,75 +2,12% 8,53% 597.900
21/01/2022 32,24 33,00 31,06 31,09 -3,95% 6,02% 635.500
20/01/2022 33,58 35,05 32,32 32,37 -3,37% 8,13% 657.600
19/01/2022 34,48 35,13 33,16 33,50 -2,50% 5,71% 705.000
18/01/2022 34,97 35,48 34,25 34,36 -4,05% 3,52% 742.700
14/01/2022 35,92 36,56 34,77 35,81 -1,62% 4,98% 644.300
13/01/2022 37,09 37,40 36,27 36,40 -1,57% 3,05% 661.700
12/01/2022 38,59 38,97 36,47 36,98 -5,93% 6,48% 1.013.600
11/01/2022 37,70 39,93 37,21 39,31 +4,66% 7,21% 1.140.800
10/01/2022 37,39 37,64 35,39 37,56 +0,54% 6,02% 1.027.800
07/01/2022 38,16 39,69 36,79 37,36 -2,81% 7,59% 685.500
06/01/2022 38,68 40,36 38,29 38,44 -1,21% 5,35% 855.600
05/01/2022 40,29 40,75 38,90 38,91 -3,43% 4,59% 572.800
04/01/2022 41,48 41,95 39,46 40,29 -3,68% 6,00% 382.100
03/01/2022 40,51 42,05 40,06 41,83 +3,36% 4,92% 911.500
31/12/2021 41,90 43,01 40,31 40,47 -3,53% 6,44% 197.800
30/12/2021 42,05 43,53 41,70 41,95 -0,55% 4,35% 186.000
29/12/2021 43,09 43,51 41,85 42,18 -2,02% 3,85% 210.300
28/12/2021 43,77 44,77 43,01 43,05 -1,94% 4,02% 189.600
27/12/2021 45,00 45,90 43,77 43,90 -1,55% 4,73% 361.600
23/12/2021 41,94 44,84 41,01 44,59 +6,65% 9,13% 729.000
22/12/2021 41,00 42,04 39,98 41,81 +2,35% 5,02% 1.020.300
21/12/2021 41,00 41,33 39,40 40,85 -1,87% 4,71% 780.600
20/12/2021 40,90 42,45 40,01 41,63 +0,07% 5,96% 2.100.600
17/12/2021 38,66 42,15 37,84 41,60 +5,69% 11,15% 1.692.700
16/12/2021 40,74 41,11 39,03 39,36 -2,86% 5,11% 694.700
15/12/2021 39,32 40,93 38,01 40,52 +3,10% 7,43% 927.300
14/12/2021 40,26 40,42 38,61 39,30 -3,37% 4,50% 575.600
13/12/2021 40,74 41,37 39,93 40,67 -0,05% 3,53% 513.200
10/12/2021 42,77 43,09 40,66 40,69 -4,51% 5,68% 679.500